摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[苄氧羰基]-D-谷氨酸 1-甲基酯 | 26566-11-0

中文名称
N-[苄氧羰基]-D-谷氨酸 1-甲基酯
中文别名
苄氧羰基-D-谷氨酸-甲酯;N-[苄氧羰基]-D-谷氨酸1-甲基酯
英文名称
N-(benzyloxycarbonyl)-D-glutamic acid 1-methyl ester
英文别名
1-methyl N-benzyloxycarbonyl-D-glutamate;N-Z-D-Glutamate α-methyl ester;(D)-Z-glutamic acid methyl ester;N-Cbz-D-glutamic acid 1-methyl ester;Cbz-D-Glu-OMe;Z-D-Glu-OMe;(4R)-5-methoxy-5-oxo-4-(phenylmethoxycarbonylamino)pentanoic acid
N-[苄氧羰基]-D-谷氨酸 1-甲基酯化学式
CAS
26566-11-0
化学式
C14H17NO6
mdl
——
分子量
295.292
InChiKey
BGMCTGARFXPQML-LLVKDONJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    510.6±50.0 °C(Predicted)
  • 密度:
    1.272±0.06 g/cm3(Predicted)
  • 溶解度:
    溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    21
  • 可旋转键数:
    9
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    102
  • 氢给体数:
    2
  • 氢受体数:
    6

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:24d8545aa17070cd323a2bedf264f947
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2

反应信息

  • 作为反应物:
    描述:
    N-[苄氧羰基]-D-谷氨酸 1-甲基酯 在 10percent Pd/C N-甲基吗啉 、 lithium hydroxide 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氢气三氟乙酸 作用下, 以 甲醇二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 96.0h, 生成 diammonium (N-acetyl-1,6-anhydro-muramyl)-L-alanyl-Nα-(D-isoglutamyl)-(2S,6R)-2,6-diaminopimelate
    参考文献:
    名称:
    Synthesis of Muramyl Peptides Containing meso-Diaminopimelic Acid
    摘要:
    Chain-extension Of L-glutamate aldehyde 3 by means of the Wittig-Homer reaction furnished the desired C-7 dicarboxylic acid derivative, which in turn, after C-C double bond hydrogenation and protecting group manipulation, afforded the 2,6-diaminopimelic acid derivatives (S,R)-9 and (S,S)-9, both with the desired orthogonal protecting group pattern. Synthesis of the muramic acid derivative 15 and attachment of an L-alanine residue furnished muramyl-L-alanine 18. The corresponding 1,6-anhydromuramic acid derivative 26 was obtained similarly. Treatment of these compounds with peptides 28-30 and with the 2,6-diaminopimelic acid containing di- and tripeptides 32a, 32b, and 35 gave the protected muramyl peptides 17, 37, 40, 42, 44, 46, and 49a and 49b, which, after deprotection, afforded the desired target molecules muramyl-L-alanine (38), muramyl-L-alanyl-D-glutamic acid (39), muramyl-L-alanyl-D-glutaminide (41), muramyl-L-alanyl-D-isoglutaminyl-L-lysine (43), muramyl-L-alanyl-D-isoglutaminyl-(2S,6R)-2,6-diaminopimelic acid (45), muramyl-L-alanylL-isoglutaminyl-(2S,6R)-2,6-dian-Anopimelinyl-D-alanine (47), 1,6-anhydromuramyl-L-alanyl-D-isoglutaminyl-(2S,6R)-2,6-diaminopimelic acid (50a), and 1,6-anhydromuramyl-L-alanyl-Disoglutaminyl-(2S,6S)-2,6-diaminiopimelic acid (50b). (C) Wiley-VCH Verlag GmbH, 69451 Weinheim, Germany, 2002.
    DOI:
    10.1002/1099-0690(200208)2002:16<2710::aid-ejoc2710>3.0.co;2-8
  • 作为产物:
    描述:
    参考文献:
    名称:
    (2S,5R/2R,5S)-Aminoethylpipecolyl aepip-aegPNA chimera: synthesis and duplex/triplex stability
    摘要:
    This article reports the design and facile synthesis of novel chiral six-membered PNA analogues (2S,5R/2R,5S)-1-(N-Boc-aminoethyl)-5-(thymin-1-yl)pipecolic acid, aepipPNA IV that upon incorporation into standard aegPNA sequences effected stabilization of complexes with complementary target DNA. Substitution of aegPNA unit by the designed monomer at the C-terminus was more effective than substitution at N-terminus. The stabilizing behaviour improved with degree of substitution and was found to be dependent on their relative positions in the sequence. The six-membered piperidine ring in the design may freeze the rigid chair conformations and the relative stereochemistry of the substituents may in effect direct the complex formation with DNA/RNA by sequence-specific nucleobase recognition. In the present aepipPNA analogues, the L-trans stereochemical disposition of the substituents seems to lead to the favorable pre-organization of the PNA oligomers for complex formation with DNA. The results reported here further expand the repertoire of cyclic PNA analogues. (C) 2004 Published by Elsevier Ltd.
    DOI:
    10.1016/j.tet.2004.07.080
点击查看最新优质反应信息

文献信息

  • Photodecarboxylative Amination of Redox-Active Esters with Diazirines
    作者:Vishala Maharaj、Preeti P. Chandrachud、Wen Che、Lukasz Wojtas、Justin M. Lopchuk
    DOI:10.1021/acs.orglett.1c03344
    日期:2021.11.19
    Diazirines have been recently demonstrated to serve as electrophilic amination reagents that afford diaziridines, versatile heterocycles that are readily transformed into amines, hydrazines, and nitrogen-containing heterocycles. Here, we report the photodecarboxylative amination of redox-active esters with diazirines using inexpensive photoactivators under mild conditions with an enhanced scope for
    最近已证明二氮丙啶可用作亲电胺化试剂,可提供二氮丙啶、多种杂环,这些杂环很容易转化为胺、肼和含氮杂环。在这里,我们报告了在温和条件下使用廉价的光活化剂对氧化还原活性酯与二氮丙啶进行光脱羧胺化,并扩大了主要底物的范围。证明了二氮丙啶对蓝光的稳定性,为进一步研究具有这些独特杂环的其他光化学胺化方法铺平了道路。
  • Synthesis towards microcystins and related toxins
    作者:Hong Yong Kim、Karin Stein、Peter L. Toogood
    DOI:10.1039/cc9960001683
    日期:——
    A general route is described for the preparation of microcystins and nodularins, including new chemistry for the preparation of β-methyl-D-aspartic acid.
    文中描述了一般制备微囊藻毒素和节球藻毒素的路线,包括制备β-甲基-D-天冬氨酸的新化学方法。
  • Facile New Method for Preparation of Optically Active Protected Proline
    作者:Jun-ichi Yamaguchi、Masaaki Ueki
    DOI:10.1246/cl.1996.621
    日期:1996.8
    Treatment of L-N-protected 2-amino-5-bromopentanoic acid ester, which was prepared from protected L-glutamic acid, with sodium hydride in tetrahydrofuran (THF) proceeded to give the corresponding protected L-proline in high yield. On the other hand, the reaction of 2-aminobutyric acid derivative with sodium hydride gave the 1-aminocyclopropane-1-carboxylic acid derivative.
    用四氢呋喃 (THF) 中的氢化钠处理由受保护的 L-谷氨酸制备的 LN 保护的 2-氨基-5-溴戊酸酯,以高产率得到相应的保护 L-脯氨酸。另一方面,2-氨基丁酸衍生物与氢化钠反应得到1-氨基环丙烷-1-羧酸衍生物。
  • Total Synthesis of Dansylated Park's Nucleotide for High-Throughput MraY Assays
    作者:Stephanie Wohnig、Anatol P. Spork、Stefan Koppermann、Gottfried Mieskes、Nicolas Gisch、Reinhard Jahn、Christian Ducho
    DOI:10.1002/chem.201604279
    日期:2016.12.5
    membrane protein translocaseI (MraY) is a key enzyme in bacterial peptidoglycan biosynthesis. It is therefore frequently discussed as a target for the development of novel antibiotics. The screening of compound libraries for the identification of MraY inhibitors is enabled by an established fluorescence‐based MraY assay. However, this assay requires a dansylated derivative of the bacterial biosynthetic
    膜蛋白转位酶I(MraY)是细菌肽聚糖生物合成中的关键酶。因此,经常将其作为开发新型抗生素的靶标进行讨论。通过已建立的基于荧光的MraY分析,可以筛选用于鉴定MraY抑制剂的化合物库。然而,该测定需要细菌生物合成中间体Park的核苷酸的丹磺酰化衍生物作为MraY底物。从细菌中分离出Park的核苷酸并随后进行丹磺酰化只能提供有限量的这种底物,从而妨碍了高通量筛选MraY抑制剂。因此,在提供这种有希望的药物靶标时,有效提供丹磺酰化的Park核苷酸是一个主要的瓶颈。在这项工作中,
  • Synthesis of carbosilane dendritic wedges and their use for the construction of dendritic receptors
    作者:Rieko van Heerbeek、Paul C. J. Kamer、Piet N. M. W. van Leeuwen、Joost N. H. Reek
    DOI:10.1039/b514583j
    日期:——
    A divergent route for the synthesis of carbosilane wedges that contain either a bromine or amine as focal point has been developed. These new building blocks enable the construction of various core-functionalized carbosilane dendrimers. As a typical example carbosilane dendrimers up to the third generation containing a N,N',N''-1,3,5-benzenetricarboxamide core (G1-G3) have been synthesized. This new
    已经开发了用于合成包含溴或胺作为焦点的碳硅烷楔的不同途径。这些新的构建基块可以构建各种核心功能化的碳硅烷树枝状聚合物。作为典型的例子,已经合成了直至第三代的含N,N′,N′-1,3,5-苯三甲酰胺核心(G1-G3)的碳硅烷树状大分子。已经研究了这类新型分子作为宿主分子,并且发现它们通过氢键相互作用与受保护的氨基酸结合为客体分子。对于较高年龄的树突状宿主,观察到缔合常数降低,这归因于结合位点所在的核周围的空间位阻增加。可以通过修饰碳硅烷树状大分子核心处的结合基序来调节树状主体分子的结合特性。当第三代N,N',N''-1,3,5-三(L-丙氨酸)苯三甲酰胺核心功能化后,N-CBZ保护的谷氨酸1-甲酯(5)的缔合常数更高。与G3相比,碳硅烷树状聚合物(G3')被用作主体分子。非对映异构体G3'.L-5(K = 295 M(-1))和G3'。(D-5)(2)(K = 236 M(-1))主宾的形成
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物